Literature DB >> 21837777

Can the prostate risk calculator based on Western population be applied to Asian population?

Duck Ki Yoon1, Jae Young Park, Sungroh Yoon, Man Sik Park, Du Geon Moon, Jeong Gu Lee, Fritz H Schröder.   

Abstract

BACKGROUND: We developed a korean prostate cancer risk calculator (KPCRC) for predicting the probability of a positive initial prostate biopsy using clinical and laboratory data from a Korean male population (http://pcrc.korea.ac.kr). We compared its performance to prostate-specific antigen (PSA) testing and the Prostate Risk Calculator 3 (PRC 3) based on data from the Dutch part of European Randomized Study of Screening for Prostate Cancer (ERSPC), which predicts biopsy results for previously unscreened men.
METHODS: Data were collected from 602 Korean men who were previously unscreened and underwent initial ten-core prostate biopsies. Multiple logistic regression analysis was performed to determine the significant predictors. Area under the receiver operating characteristic curve (AUC) and calibration plots of both calculators were evaluated.
RESULTS: Prostate cancer (PCa) was detected in 172 (28.6%) men. Independent predictors of a positive biopsy included advanced age, elevated PSA levels, reduced volume of the transition zone, and abnormal digital rectal examination findings. The AUC of the KPCRC was higher than the PRC 3 and PSA alone on internal and external validation. Calibration plots of the KPCRC showed better performance than the other models on internal and external validation. Applying a cut-off of 10% of KPCRC implied that 251 of the 602 men (42%) would not have been biopsied and that 12 of the 172 PCa cases (7%) would not have been diagnosed.
CONCLUSIONS: The KPCRC improves the performance of the PRC 3 and PSA testing in predicting Korean population's risk of PCa. It implies that Asian populations need their own risk calculators for PCa.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837777     DOI: 10.1002/pros.21475

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  15 in total

1.  A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer.

Authors:  Ping Tang; Hui Chen; Matthew Uhlman; Yu-Rong Lin; Xiang-Rong Deng; Bin Wang; Wen-Jun Yang; Ke-Ji Xie
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

Review 2.  The effect of ethnicity and sexual preference on prostate-cancer-related quality of life.

Authors:  Nir Kleinmann; Nicholas G Zaorsky; Timothy N Showalter; Leonard G Gomella; Costas D Lallas; Edouard J Trabulsi
Journal:  Nat Rev Urol       Date:  2012-04-10       Impact factor: 14.432

3.  Ductal adenocarcinoma of the prostate: a Hong Kong case series.

Authors:  Raymond Wai Man Kan; Chi Fai Kan; Joseph Hon Ming Wong; Kenneth Kam Fung Fu; Chi Fai Ng; Steve Wai Hee Chan
Journal:  Int Urol Nephrol       Date:  2014-07-31       Impact factor: 2.370

4.  External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.

Authors:  Yao Zhu; Jin-You Wang; Yi-Jun Shen; Bo Dai; Chun-Guang Ma; Wen-Jun Xiao; Guo-Wen Lin; Xu-Dong Yao; Shi-Lin Zhang; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2012-05-07       Impact factor: 3.285

5.  Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men.

Authors:  Chang Wook Jeong; Sangchul Lee; Jin-Woo Jung; Byung Ki Lee; Seong Jin Jeong; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

6.  A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients.

Authors:  Yuan Huang; Gong Cheng; Bianjiang Liu; Pengfei Shao; Chao Qin; Jie Li; Lixin Hua; Changjun Yin
Journal:  BMC Urol       Date:  2014-01-11       Impact factor: 2.264

7.  Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsies.

Authors:  Ruizhe Zhao; Yuan Huang; Gong Cheng; Jinliang Liu; Pengfei Shao; Chao Qin; Lixin Hua; Changjun Yin
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

8.  Rotterdam Prostate Cancer Risk Calculator: Development and Usability Testing of the Mobile Phone App.

Authors:  Nuno Pereira-Azevedo; Luís Osório; Avelino Fraga; Monique J Roobol
Journal:  JMIR Cancer       Date:  2017-01-06

9.  Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA.

Authors:  Jing Zhao; Shuai Liu; Dexuan Gao; Sentai Ding; Zhihong Niu; Hui Zhang; Zhilong Huang; Juhui Qiu; Qing Li; Ning Li; Fang Xie; Jilei Cui; Jiaju Lu
Journal:  Oncotarget       Date:  2017-02-07

10.  Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.

Authors:  Jae Young Park; Sungroh Yoon; Man Sik Park; Hoon Choi; Jae Hyun Bae; Du Geon Moon; Sung Kyu Hong; Sang Eun Lee; Chanwang Park; Seok-Soo Byun
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.